Estimation of serum level of pS2 protein in patients with lung adenocarcinoma

Anticancer Research

Volumn 16, Issue 4 B, 1996, Pages 2351-2355

  Higashiyama, Masahiko ^a   Doi, Osamu ^a   Kodama, Ken ^a   Yokuchii, Hideoki ^a   Inaji, Hideo ^a   Tateishi, Ryuhei ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Bronchioloalvcolar type; Goblet cell subtype; Lung adenocarcinoma; pS2 protein; Serum level; Tumor marker

Indexed keywords

PROTEIN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; FEMALE; GOBLET CELL; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADENOCARCINOMA; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0029813476     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, and Chambon P: Cloning of cDNA sequences of hormone regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10: 7895-7903, 1982.
2. Jakowlew SB, Breathnach R, Jeltsch JM, Masiakowski P, and Chambon P: Sequence of the pS2 mRNA induced by estrogen in human breast cancer cell line MCF-7. 12: 2861-2878, 1984.
3. Foekens JA, Rio M-C, Seguin P, van Putten W, Fauque J, Nap M, Klijin J, and Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50: 3832-3837, 1990.
4. Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP, Chambon P, and Thor AD: pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 51: 624-628, 1991.
5. Koerner FC, Goldberg DE, Edgerton SM, and Schwartz LH: pS2 protein and steroid hormone receptors in invasive breast carcinomas. Int J Cancer 52: 183-188, 1992.
6. Henry JA, Bennett MK, Piggot NH, Levett DL, May FEB, and Westley BR: Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer 64: 677-682, 1991.
7. Luqmani YA, Ryall G, Shousha S, and Coomes RC: An immunohistochemical survey of pS2 expres6ion in human epithelial cancers. Int J Cancer 50: 302-304, 1992.
8. Rio M-C, and Chambon P: The pS2 gene, mRNA, and protein: a potential marker for human breast cancer. Cancer Cells 2: 269-274, 1990.
9. Miyashita S, Nomoto H, Konishi H, and Hayashi K: Estimation of pS2 protein level in human body fluid by a sensitive two-site enzyme immunoassay. Clin Chim Acta 228: 71-81, 1994.
10. Higashiyama M, Doi O, Kodama K, Yokouchi H, Inaji H, Nakamori S, and Tateishi R: Prognostic significance of pS2 protein expression in pulmonary adenocarcinoma. Eur J Cancer, 30A: 792-797, 1994.
11. Mountain CF: A new international staging system for lung cancer. Chest 89: 225-232, 1986.
12. The Japan Lung Cancer Society: General Rule for Clinical and Pathological Record of Lung Cancer, ed 4, Tokyo, Kanehara Shuppan, pp90-98, 1995.
13. Goussard J, Lechevrel C, Roussel G, Cren H, Bera O, and Sala M: Immunoradiometric assay of pS2 protein in breast cancer cytosols. Clin Chem 37: 1759-1762, 1991.
14. Correale M, Paradiso A, Abbate I, Margia A, Dragone CD, Tedone T, Filotico R, Schittulli F, and De Lena M: Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity. Tumor Biol 14: 30-37, 1993
15. Thim L: A new family of growth factor-like peptides. "Trefoil" Disiphide loop structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP), and frog skin peptides (spasmolysins). FEBS Lett 250: 85-90, 1989.
16. Hoosein NM, Thim L, Jorgensen KH, and Brattain MG: Growth stimulatory effect of pancreatic spasmolytic polypeptide on cultured colon and breast tumor cells. FEBS Lett 247: 303-306, 1989.